Evidence map›Paper›PMID 36153349›Full record

ArticleNPJ vaccines2022

Dithranol as novel co-adjuvant for non-invasive dermal vaccination.

Julian Sohl, Ann-Kathrin Hartmann, Jennifer Hahlbrock, Joschka Bartneck, Michael Stassen, Matthias Klein, Matthias Bros, Stephan Grabbe, Federico Marini, Kevin Woods and 8 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Cross-presenting Langerhans cells are required for the early reactivation of resident CD8Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Article
  5. Tumor-infiltrating CCR2Frontiers in immunology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Julian SohlIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Ann-Kathrin HartmannIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Jennifer HahlbrockInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Joschka BartneckIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Michael StassenInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Matthias KleinInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Matthias BrosResearch Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Stephan GrabbeResearch Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Federico MariniResearch Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.ORCID http://orcid.org/0000-0003-3252-7758
Kevin WoodsIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Borhane GuezguezIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.ORCID http://orcid.org/0000-0002-1474-8074
Matthias MackDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-3157-7262
Hansjörg SchildInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Sabine MuthInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Felix MelchiorInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.ORCID http://orcid.org/0000-0002-7113-9857
Hans Christian ProbstInstitute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Peter LangguthResearch Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Markus P RadsakIIIrd Department of Medicine - Hematology & Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. radsak@uni-mainz.de.ORCID http://orcid.org/0000-0002-3991-5721
Johannes Gutenberg University Mainz · DEGerman Cancer Research Center · DEUniversity Hospital Regensburg · DE

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 1066Deutsche Forschungsgemeinschaft (German Research Foundation) 318346496Deutsche Forschungsgemeinschaft (German Research Foundation) CRC1066Deutsche Forschungsgemeinschaft (German Research Foundation) TR156-KS01
6 · The paper itself

Abstract

Transcutaneous immunization (TCI) utilizing the TLR7 agonist imiquimod (IMQ-TCI) induces T cell-driven protective immunity upon application onto intact skin. In our present work, we combine the anti-psoriatic agent dithranol with IMQ-TCI to boost vaccination efficacy (Dithranol/IMQ-based transcutaneous vaccination (DIVA)). Using ovalbumin-derived peptides as model antigens in mice, DIVA induced superior cytolytic CD8

Identifiers

PMID36153349
PMCPMC9509335
OpenAlexW4296977104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.